December 8, 2016 / 2:00 PM / 7 months ago

BRIEF-Gilead Sciences submits new drug application to U.S. FDA for Hepatitis C

1 Min Read

Dec 8 (Reuters) - Gilead Sciences Inc

* Gilead Sciences Inc - nda for sof/vel/vox is based on data from two phase 3 studies (polaris-1 and polaris-4)

* Gilead submits new drug application to U.S. Food and drug administration for the investigational single tablet regimen sofosbuvir/velpatasvir/voxilaprevir Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below